{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-027953","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.962631+00:00","generated_at":"2026-05-15T11:58:39.861375+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alto Neuroscience raises $120M via PIPE to fund ALTO-207 Phase 3 in TRD","bullets":["Gross proceeds ~$120M from sale of 2.9M shares at $20.00 and 3.1M pre-funded warrants at $19.9999.","Financing led by Commodore Capital with participation from new and existing biotech investors.","Proceeds to fund ALTO-207 (pramipexole/ondansetron combo) through planned Phase 3 TRD study and potential NDA.","Plan to initiate ALTO-207 Phase 2b in H1 2026 and Phase 3 in early 2027; pro forma cash ~$275M as of Feb 28, 2026.","Closing expected March 17, 2026; Jefferies, BofA, TD Cowen, Stifel, William Blair, Baird as placement agents."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-027953","json":"https://secwatch.observer/filing/0001104659-26-027953.json","markdown":"https://secwatch.observer/filing/0001104659-26-027953.md","text":"https://secwatch.observer/filing/0001104659-26-027953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926027953/0001104659-26-027953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926027953/tm268876d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:58:39.861375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1894b54b11c68fa282aa0ecb795fdf083ef29cc","claim":"Alto Neuroscience, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $120.0 million (effective 2026-03-16).","evidence_excerpt":"On March 16, 2026, Alto Neuroscience, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain institutional investors (the “ Purchasers ”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction (the “ Private Placement ”) (i) 2,900,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 (“ Common Stock ”), and (ii) with respect to certain Purchasers, pre-funded warrants to purchase 3,100,000 shares of Common Stock (the “ Pre-Funded Warrants ”) in lieu of Shares.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926027953/0001104659-26-027953-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $120.0 million"},{"label":"Effective","value":"2026-03-16"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}